anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In this arm, the children received, orally, the combination of midazolam and ketamine. Midazolam, at a dose of 0.5 mg/kg (maximum dose 20 mg) and ketamine, at a dose of 3 mg/kg (maximum dose 50 mg). This combination of drugs were administered fifteen minutes before the start of treatment sessions.
INTRODUCTION: Soldiers must be able to perform a multitude of physically demanding tasks as part of their regular duty, but their physical readiness is often degraded due to pain and musculoskeletal injury (MSKI). The presence of pain with movement has been associated with increased MSKI risk in Soldiers. Improved awareness of the prevalence of painful movements in uninjured Soldiers could help inform Army injury mitigation efforts. The purpose of this study was to identify the prevalence of pain with movement in a population of healthy active duty Soldiers.
MATERIALS AND METHODS: The Selective Functional Movement Assessment-Top Tier Movements (SFMA-TTM), active range of motion (AROM) of the hips and shoulders, and the elicitation of pain with movement were measured in 268 healthy US Army Soldiers. Descriptive statistics were generated for the number of painful movements for each measure and inferential statistics; independent t-test and one-way independent analysis of variance (ANOVA) were used for analysis of the other measures.
RESULTS: Greater than half (59%) of the participants reported pain with at least 1 movement and more than 41% reported pain with 2 or more movements. Soldiers reported a mean of 1.35 painful movements on the SFMA-TTM assessment and a mean of 1.54 painful AROM movements.
CONCLUSIONS: Pain with functional movement patterns was common across a sample of uninjured Soldiers. The presence of pain with movement warrants further evaluation as it may impact a Soldier's physical performance, risk for future injury, and overall quality of life.
Oral mucositis (OM) is the most common and refractory complication of cancer chemotherapy and radiotherapy, severely affecting patients' life quality, lowering treatment tolerance, and discouraging patient compliance. Current OM delivery systems mostly affect the comfort of patient use and lead to poor compliance and unsatisfactory effects. Herein, salivary amylases (SAs)-responsive buccal tablets consisting of porous manganese-substituted Prussian blue (PMPB) nanocubes (NCs), anti-inflammatory apremilast (Apr) and starch controller have been engineered. PMPB NCs with large surface area can serve as carriers to load Apr, and their multienzyme-mimicking activity enables them to scavenge reactive oxygen species (ROS), which thus synergize with Apr to mitigate inflammation. More significantly, the starch controller can respond to abundant SAs in the oral cavity and realize the cascade, continuous, and complete drug release after enzymatic decomposition, which not only aids with high tissue affinity to prolong the resistance time but also improves the comfort of use. The preclinical study reveals that contributed by the above actions, such buccal tablets mitigate inflammation, promote endothelium proliferation and migration, and accelerate wound healing for repressing chemotherapy-originated intractable OM with positive oral microenvironment and shorter recovery time, thus holding high potentials in clinical translation.
Drug: DTRI-031 Single doses of DTRI-031 delivered via intravenous injection. Ascending dose levels will be evaluated.
Patients undergo DCE-MRI over 45-60 minutes. Patients receive technetium Tc-99m sestamibi via injection, and after 5 minutes patients undergo MBI scan over 1 hour. Both DCE-MRI and MBI are performed at the time of enrollment, at the end of anthracycline therapy, and at the conclusion of NAC before surgery. All patients also undergo standard of care imaging with DM and US (at the same time points if the treating doctor chooses to do so).
Many of the medications that clinicians prescribe to prevent or treat disease can result in unanticipated and unintended toxic effects. Many national clinical guidelines recommend baseline and periodic laboratory monitoring to avoid adverse drug events. Our Safety in Prescribing project (SIP) has found many significant gaps in medication safety. Lab Alert will evaluate electronic tools to improve Kaiser Permanente's performance in laboratory monitoring to avoid adverse drug events. We will enroll patients who are taking high-risk medications and who have not received laboratory monitoring. The primary outcome of this 2-year study is the proportion of patients who receive guideline-based laboratory monitoring at 1 and 3 weeks post-intervention.

Fifteen primary care clinics will be randomly assigned to: (1) usual care (UC) (2) electronic message reminder (EMR) (3) automated voice message (AVM) (4) pharmacy outreach team (Pharmacy). The reminders will notify of the patient's need for guideline-specified laboratory testing due to medication use. Using electronic data, patients with PCPs assigned to intervention clinics who are on study-specified medications will be identified and screened for exclusions, to yield 600 patients (200 per intervention group). Patients will be assigned to the treatment groups on the basis of the condition assigned to their usual clinic. After the intervention and observation periods, and using the same time frame and inclusion and exclusion criteria used to identify the patients in the intervention arms, we will retrospectively identify a comparison 200-patient cohort in the usual care clinics. Thus, approximately 800 patients will be included in the study. Baseline, follow-up, and outcome data will be obtained from electronic records.

Study-defined medications will be finalized by the study team and quality committees. These medications are identified based upon previous work and are prescribed with reasonable frequency, commonly have gaps in laboratory monitoring, carry significant risk of toxicity, and are of interest to the participating HMOs because of prior and potential adverse events. We anticipate focusing on baseline monitoring for new prescriptions. New starts will be defined as patients with an index prescription but no other dispense of that medication in the prior 6 months.

Lab Alert will assess the effectiveness of a patient-specific electronic medical record (EMR) in-basket reminder to the primary care provider (PCP) (EMR reminder), an automated recorded voice message to the patient (AVM), pharmacy team outreach (Pharmacy) to increase the proportion of patients receiving all guideline-based laboratory monitoring, when compared to usual care (UC). If any intervention is better than UC, Lab Alert will assess and compare their effectiveness and costs. The study also will evaluate PCP and patient experiences with the intervention in order to refine the interventions in the future.
The complexity of the mechanisms underlying metabolic dysfunction-associated steatotic liver disease (MASLD) progression remains a significant challenge for the development of effective therapeutics. miRNAs have shown great promise as regulators of biological processes and as therapeutic targets for complex diseases. Here, we study the role of hepatic miR-33, an important regulator of lipid metabolism, during the progression of MASLD and the development of hepatocellular carcinoma (HCC). We report that miR-33 was elevated in the livers of humans and mice with MASLD and that its deletion in hepatocytes (miR-33 HKO) improved multiple aspects of the disease, including steatosis and inflammation, limiting the progression to metabolic dysfunction-associated steatotic hepatitis (MASH), fibrosis, and HCC. Mechanistically, hepatic miR-33 deletion reduced lipid synthesis and promoted mitochondrial fatty acid oxidation, reducing lipid burden. Additionally, absence of miR-33 altered the expression of several known miR-33 target genes involved in metabolism and resulted in improved mitochondrial function and reduced oxidative stress. The reduction in lipid accumulation and liver injury resulted in decreased YAP/TAZ pathway activation, which may be involved in the reduced HCC progression in HKO livers. Together, these results suggest suppressing hepatic miR-33 may be an effective therapeutic approach to temper the development of MASLD, MASH, and HCC in obesity.
The present invention provides methods and compositions for enhancing the diffusion of therapeutic agents through mammalian tissue. In one embodiment, invention provides methods and compositions useful for enhancing the diffusion of gene therapy vectors through a mammalian tissue of interest. The method comprises delivering the therapeutic agent and a permeabilizer to the tissue of interest. The method may further comprise inducing hyperthermia in the tissue. In one embodiment, a composition in accordance with the present invention comprises a gene therapy vector containing a polynucleotide and a tissue permeabilizer. A method of destroying tissue is also provided. In one embodiment of this aspect of the invention, the method includes delivering a high concentration of tissue permeabilizer to the tissue and may also include inducing hyperthermia in the tissue.
The embodiment of the specification discloses an antibody targeting PSGL-1 protein and application thereof. The antibody may comprise: an antibody targeting human PSGL-1 comprising a light chain and a heavy chain, wherein: the light chain comprises the amino acid sequence of SEQ ID NO. 1 and the heavy chain comprises the amino acid sequence of SEQ ID NO. 5; alternatively, the light chain comprises the amino acid sequence of SEQ ID NO. 9 and the heavy chain comprises the amino acid sequence of SEQ ID NO. 13. The antibody provided by the invention can inhibit inflammatory reaction, and is applied to medicines for treating or preventing inflammatory diseases.
1. A composition comprising an anti-tumor drug conjugated to a water soluble polymer or metal chelator and wherein said a water soluble polymer or metal chelator is selected from the group consisting of poly (d-glutamic acid), poly (l-glutamic acid), poly (dlglutamic acid), poly (d-aspartic acid), poly (l-aspartic acid), poly (dl-aspartic acid)and copolymers thereof, where the anti-tumor drug is paclitaxel, docetaxel, etopside, teniposide camptothecin or epothilone. 2. The composition of claim 1 wherein the anti-tumor drug is selected from paclitaxel, docetaxe and camptothecin. 3. The composition of claim 2, wherein said polymer is further defined as a copolymer with polycaprolactone, polyglycolic acid and polylactic acid. 4. The composition of any preceding claim, wherein said polymer/copolymer has a molecular weight of from about 5,000 to about 100,000, preferably from about 20,000 to about 80,000. 5. The composition of any preceding claim, wherein said water soluble polymer is conjugated to the 2'-and/or the 7-hydroxyl of paclitaxel or docetaxel. 6. The composition of any preceding claim, comprising from 2 to 35% by weight of said anti-tumor drug. 7. The composition of claim 1, wherein paclitaxel is conjugated with polyglutamic acid. 8. Use of said composition of any preceding claim of treating cancer for decreasing at least one symptom of a systemic autoimmune disease and for inhibiting arterial restenosis or arterial occlusion following vascular trauma. 9. Use of claim 8, wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, colon cancer, head and neck cancer or leukemia or or Kaposi's sarcoma.  10. An implantable medical device, in particular stent, wherein said device is coated with a composition comprising paclitaxel conjugated to water soluable polyamino acids in an amount effective to inhibit smooth muscle cell proliferation.
In addition to general improvement changes, subjects exposed to the in-line help text arm receive text detailing evidence-based transfusion recommendations that appear if the most recent hemoglobin level is above 7.0 g/dL. This text appears within the transfusion order but is non-interruptive as it does not require users to acknowledge the text nor does is require any additional keystrokes or clicks.
Methods are provided for quenching undesired side reactions of pathogen inactivating compounds in biological materials. In a particular embodiment, methods are provided for quenching undesired side reactions of a pathogen inactivating compound that includes a functional group which is, or which is capable of forming, an electrophilic group. In this embodiment, the material is treated with the pathogen inactivating compound and a quencher, wherein the quencher comprises a nucleophilic functional group that is capable of covalently reacting with the electrophilic group. The electrophilic group on the pathogen inactivating compound is preferably a non-radical cationic group.  In one embodiment, the pathogen inactivating compound includes a nucleic acid binding ligand and a mustard group, wherein the mustard group is capable of reacting in situ to form the electrophilic group. Preferred quenchers are thiols, such as glutathione. Biological materials which may be treated include whole blood, red blood cells, blood plasma, and platelets. The methods permit inhibition of the modification of red blood cells in red blood cell containing materials during pathogen inactivation.
The invention relates to amines, in particular a method of producing N-[2-(4-fluoro-phenyl)-1-methyl]-ethyl-N-methyl-N-propynyl amine or pharmacologically acceptable salts thereof in the form of racemate or the optically active isomer, possessing antidepressive activity that can be used in medicine. The invention provides creation of new more active compounds of the specified class. Synthesis is carried out by the reaction n-fluorophenilacetone with amine of formula HNR1R2, where R1-H or propinil, R2-H or methyl. The obtained ketimine or hydramine is reduced and in case if R1-H, it is propinilated and if R2-H, it is methylated. The final product is extracted in the form of free base or pharmacologically acceptable salt in the form of racemate or optically active isomer. The tests show, that new compounds are very active selective inhibitors of monoamino oxidaze of B type and inhibitors of absorption of tyramine and biogenic amines.
CAMCEVI is a sterile formulation of leuprolide mesylate for subcutaneous injection. CAMCEVI is designed to deliver approximately 42 mg of leuprolide over 6 months.

Leuprolide mesylate is a synthetic nonapeptide analog of naturally occurring GnRH and is a GnRH agonist. The analog possesses greater potency than the natural hormone. The chemical name is 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide mesylate (salt) with the following structural formula. The pH of 50 mg/mL solution of leuprolide mesylate in water is approximately 5.7.

CAMCEVI is supplied as a kit with a pre-filled, single-dose, sterile syringe for subcutaneous injection. Each pre-filled syringe delivers 42 mg leuprolide (equivalent to approximately 48 mg leuprolide mesylate), poly(D, L-lactide) (184 mg) polymer and N-methyl-2-pyrrolidone (136 mg).
PROBLEM TO BE SOLVED: To provide an incense sheet, which is easy to handle and can be used in many original shapes according to the users, and a manufacturing method thereof. SOLUTION: A first Japanese paper strip 25 is drawn out from a first delivery roll 23. Liquid incense material 33 stored in a material container 31 is applied onto the paper strip 25 as viscous incense material 35 by the rotation of a rotation roller 28b. A second Japanese paper strip 40 drawn out from a second delivery roll 38 is disposed on the bottom face of the viscous incense material 35, and a three-ply sheet 42 comprising the first Japanese paper strip 25, the viscous incense material 35 and the second Japanese paper strip 40 is discharged. The three-ply sheet 42 is delivered to a heater 43 and is heated. The viscous incense material 35 is hardened by the evaporation of its moisture and integrates with the first and second Japanese paper strips 25 and 40. A cutter 45 cuts the sheet and the incense sheet 11 is manufactured.
The invention discloses a compound Dai medicine extract with liver-protecting effect and a preparation method thereof. The compound Dai medicine extract is extracted from Dai medicines, such as Clerodendranthus spicatus (Thunb.)C.Y.Wu ex H.W.Li, Cassytha filiformis Linn. and Arcangelisia loureiri (Pier.)Diels. The invention also discloses a method for extracting the compound Dai medicine extract. The compound Dai medicine extract disclosed by the invention can be used for preparing liver-protecting medicines or health-care products.
A staphylococcal vaccine is produced by extracting the intact cells of Staphylococcus aureus strains NRRL B-2467, NRRL B-2468, NRRL B-2469, NRRL B-2471, NRRL B-2472, NRRL B-2473, NRRL B-2474, NRRL B-2475, NRRL B-2476 or NRRL B-2477 with phenol and an aqueous solvent to obtain immiscible phenolic and aqueous solutions, e.g. water or an aqueous physiological salt solution, and separating the phenol and insoluble solid material from the aqueous solution to obtain an aqueous solution capable of stimulating the production of a protective antibody against Staphylococcus aureus. The cells of S. aureus may be alive, killed or partially killed. The extraction steps may be carried out separately or simultaneously.  In the case of simultaneous extraction, sufficient phenol is used to produce a phenolic phase but insufficient to dissolve all the aqueous solvent phase.  For separate extractions, the phenol must contain sufficient water to render the phenol liquid but insufficient to cause separation of a separate aqueous phase i.e. 5 to 30 and preferably 15% water.  The final aqueous product should contain not more than 0.2% phenol. Excess phenol is removed by (a) dialysis or (b) extraction with a volatile water-immiscible organic solvent for the phenol e.g. ether or chloroform.  The pH of the vaccine may be adjusted to 6 to 8 and preferably pH 7.2.  If necessary, it should be made isotonic with sodium chloride.  It is sterilized for parenteral injection.
Safe use of thiothixene during pregnancy has not been established. Therefore, this drug should be given to pregnant patients only when, in the judgment of the physician, the expected benefits from the treatment exceed the possible risks to mother and fetus. Animal reproduction studies and clinical experience to date have not demonstrated any teratogenic effects.

In the animal reproduction studies with thiothixene, there was some decrease in conception rate and litter size, and an increase in resorption rate in rats and rabbits. Similar findings have been reported with other psychotropic agents. After repeated oral administration of thiothixene to rats (5 to 15 mg/kg/day), rabbits (3 to 50 mg/kg/day), and monkeys (1 to 3 mg/kg/day) before and during gestation, no teratogenic effects were seen.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to anesthesiology and resuscitation, and can be used in states accompanied by massive blood loss. For this purpose, 5 and 3 days prior to a surgery, autoblood is sampled in amount 10 % of circulating blood volume (CBV) in each sampling to be divided on plasma and erythrocyte concentrate. For 5 preoperative days, iron preparations are administered in a therapeutic dose. Also, the surgery is preceded with analysing patient's fluid deficiency. 40 minutes prior to the surgery, 12.5 % dicynone 500 mg, one volume of autoplasma are introduced, and infusion of a rated dose of 5 % glucose and 6 % hydroxyethyl starch (HES) 500 ml is started. If the intraoperative blood loss is suggested to be 15-30 % of the CBV, additionally 6 % HES 250 ml, prednisolone in dosage 2-4 mg/kg of body weight and one volume of erythrocyte concentrate are administered. If the estimated intraoperative blood loss exceeds 30 % of the CBV, the second volumes of autoplasma and erythrocyte concentrate, another introduction of dicynone in the same dosage, 6 % HES 250 ml, prednisolone in dosage 7 - 10 mg/kg of body weight are required. Within 30 and 60 minutes after the surgery, dicynone is injected in the same dosage. 5 hours after the surgery, filter drainage fluid is returned. 6 hours after the surgery, coagulation time is determined, and if observing no hypocoagulation, Clexane is introduced in a preventive dose. ^ EFFECT: method allows to provide early activation of erythropoiesis combined with improved erythrocyte morphology and blood haemostatic function, considerably reduced risk of complications connected with massive transfusion of donor blood products, as well as prevented edema of interstitial spaces and development of multiple-organ-failure syndrome due to maintained effective transcapillary exchange. ^ 5 tbl, 1 ex
Differences and/or similarities in the influence of sex class for hair sheep requirements remain inconclusive. Knowledge of energy requirements allows well-formulated diets to be provided which is crucial for improving animal production. We aimed to determine the effect of sex class on the net energy requirements of growing hair sheep in a multi-study approach. We used a data set composed of individual measurements of 382 hair sheep (299 non-castrated and 83 castrated males) from 11 studies that used the methodology of comparative slaughter. Net energy requirements for maintenance (NEm) were obtained by the regression between heat production and metabolizable energy intake. The metabolizable energy requirements for maintenance (MEm) were calculated by the iterative method, and the efficiency of use of metabolizable energy for maintenance (km) was obtained by NEm divided by MEm. The net energy requirements for gain (NEg) were estimated from retained energy (RE) against empty BW gain (EBWG). The efficiency of energy use for weight gain (kg) was obtained from the relationship between RE and the energy metabolizable intake for gain, removing the intercept. There was an effect of sex on NEg and two equations were generated: NEg (MJ/day) = 1.040 (±0.04055) × EBW0.75 × EBWG0.8767(±0.03293) and NEg (MJ/day) = 1.040 (±0.04055) × EBW0.75 × EBWG0.8300(±0.03468) (R2 = 0.86; MSE = 0.0037; AIC = -468.0) for non-castrated and castrated males, respectively. Sex class did not affect kg (P > 0.05) and one kg was generated (0.29). Sex did not affect kprotein (P = 0.14) and kfat (P = 0.32), assuming an average deposition efficiency of 0.27 for protein and 0.78 for fat. The NEm and MEm did not differ (P > 0.05) between sex classes, with a value of 0.272 and 0.427 MJ/kg0.75 EBW per day, respectively. The km observed was 0.64. In conclusion, non-castrated and castrated male hair sheep have similar maintenance energy requirements although energy requirements for gain differed among them. The Committees overestimate the gain and maintenance requirements for hair sheep. Therefore, the equations generated in this study are recommended.
After identifying the lymph node or lesion to be biopsied on ultrasound, using the endobronchial ultrasound scope, two 60mL syringes of cold saline will be inserted, through the biopsy channel of the endobronchial ultrasound scope, directly onto the bronchial wall where the biopsies are to be performed. The saline will then be sucked out of the airway using the endobronchial ultrasound scope.
The present invention discloses a Bulleyaconitine A microemulsion and the preparing method. The Bulleyaconitine A is dissolved in oil phase. Emulsifier, assistant emulsifier and other additives are added. A microemulsion which is transparent or is with slightly turbid light and is with a particle size of less than 100 nm is prepared. Compared with material drug of Bulleyaconitine A, the chemical stability and mucosa permeance capability of the drug-containing microemulsion are significantly improved. The Bulleyaconitine A microemulsion is used as releasing vector and is combined with an excipient which is acceptable on pharmacy. An appropriate preparing method is used to prepare a nasal cavity preparation which is high in biological absorption degree, safe, stable and convenient and various paper release formulation preparation. The present invention is used for the treatment of various pains.